Results 71 to 80 of about 50,528 (188)

The experience of relapsed Burkitt lymphoma treatment with targeted drugs and autologous/allogeneic stem cell transplantation

Онкогематология
The use of high-effective, multicomponent, risk-adopted chemoimmunotherapy schemes in children with Burkitt lymphoma reached advanced long-term progression-free survival over 90 % even for high risk patients.
T. T. Valiev, A. A. Khachatryan, S. V. Goryacheva, N. A. Batmanova, K. I. Kirgizov, S. R. Varfolomeeva   +5 more
doaj   +1 more source

Nucleic Acid‐Modified Nanoparticles for Cancer Therapeutic Applications

Small, EarlyView.
Nucleic acid‐modified nanoparticles act as functional hybrids for chemodynamic, photodynamic, photothermal, and gene therapy of cancer cells. These are exemplified with aptamer‐modified catalytic nanoparticles, photosensitizer‐oligonucleotide functionalized nanoparticles, drug‐loaded stimuli‐responsive nucleic acid‐caged nanoparticle carriers, and ...
Yunlong Qin, Xinghua Chen, Itamar Willner   +2 more
wiley   +1 more source

A Chinese Child Presented with Early T Cell Precursor Lymphoblastic Lymphoma

Case Reports in Hematology, 2021
T cell lymphoblastic lymphoma (T-LBL) is regarded as the leukemic phase of T cell acute lymphoblastic leukemia (T-ALL). The early T cell precursors ALL/LBL (ETP-LBL/ALL) are derived from thymic cells at the ETP differentiation stage and recognized as a ...
Xiangyang Pu, Sheng-jing Deng, N. Yin, Lin Song, Xiangling He, Jianwen Xiao   +5 more
semanticscholar   +1 more source

Nanoparticle Therapeutics in Clinical Perspective: Classification, Marketed Products, and Regulatory Landscape

Small, EarlyView.
This review presents a detailed overview of clinically approved nanoparticle therapeutics, classifying them by type and discussing their unique advantages in drug delivery. It highlights regulatory challenges across global markets and emphasizes the need for adaptive approval pathways.
Nimeet Desai, Dhwani Rana, Mitali Patel, Neha Bajwa, Rajendra Prasad, Lalitkumar K. Vora   +5 more
wiley   +1 more source

How I Treat Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (T-ALL) and T-cell Lymphoblastic Lymphoma in Children.

Blood, 2019
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy that has historically been associated with a very poor prognosis. Nevertheless, despite a lack of incorporation of novel agents, the development of intensified T-ALL focused ...
D. Teachey, D. O’Connor
semanticscholar   +1 more source

Sequential Blinatumomab with Reduced Intensity Chemotherapy in the Treatment of Older Adults with Newly Diagnosed Ph Negative B-Precursor Acute Lymphoblastic Leukemia - Interim Analysis of the Australasian Leukemia and Lymphoma Group ALL08 Study

Blood, 2021
The advent of pediatric inspired regimens has improved the outcome for younger adults with Acute Lymphoblastic Leukemia (ALL), however this comes at a considerable toxicity burden limiting its applicability in older adults.
S. Fleming, J. Reynolds, A. Bajel, N. Venn, J. Kwan, J. Moore, D. Yeung, N. Pati, M. Leahy, Joanna Nkyekyer, E. Verner, L. Berkahn, R. Sutton, A. Wei, M. Greenwood   +14 more
semanticscholar   +1 more source

CRISPR/Cas9‐edited tumor‐associated immune cells in cancer immunotherapy

VIEW, EarlyView.
Abstract Immuno‐oncology represents an emerging field that has significantly transformed tumor therapeutics, with immune cells serving as the cellular foundations of cancer immunotherapy. Due to its high efficiency and sensitivity, CRISPR/Cas9 genome editing is a highly promising technique for precise and rapid gene modification.
Yuhui Ma, Junxin Chen, Yuan Du, Zhihao Cao, Weizhi Ji, Yuyu Niu, Zebin Yang   +6 more
wiley   +1 more source

Collective Classification of Textual Documents by Guided Self-Organization in T-Cell Cross-Regulation Dynamics [PDF]

Evolutionary Intelligence. 2011. Volume 4, Number 2, 69-80, 2011
We present and study an agent-based model of T-Cell cross-regulation in the adaptive immune system, which we apply to binary classification. Our method expands an existing analytical model of T-cell cross-regulation (Carneiro et al. in Immunol Rev 216(1):48-68, 2007) that was used to study the self-organizing dynamics of a single population of T-Cells ...
arxiv   +1 more source

The role of blinatumomab in adult acute B lymphoblastic leukaemia

British Journal of Haematology, EarlyView.
Blinatumomab, a CD19‐directed bispecific T‐cell engager, has become a crucial part of BCP‐ALL therapy in r/r disease, MRD‐positive disease and has recently been implemented into first‐line therapy of BCP‐ALL. This review discusses important clinical trials with a focus on blinatumomab in first‐line therapy of adult BCP‐ALL.
Anne C. Wilke, Nicola Gökbuget
wiley   +1 more source

Broad cross-reactivity of the T-cell repertoire achieves specific and sufficiently rapid target searching [PDF]

, 2017
The molecular recognition of T-cell receptors is the hallmark of the adaptive immunity. Given the finiteness of the T-cell repertoire, individual T-cell receptors are necessary to be cross-reactive to multiple antigenic peptides. In this study, we quantify the variability of the cross-reactivity by using a string model that estimates the binding ...
arxiv   +1 more source